Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.405 USD | -1.06% | +4.44% | +149.56% |
Financials (USD)
Sales 2024 * | 72.54M | Sales 2025 * | 68.35M | Capitalization | 261M |
---|---|---|---|---|---|
Net income 2024 * | -168M | Net income 2025 * | -167M | EV / Sales 2024 * | 2.01 x |
Net cash position 2024 * | 115M | Net cash position 2025 * | 281M | EV / Sales 2025 * | -0.3 x |
P/E ratio 2024 * |
-1.67
x | P/E ratio 2025 * |
-2.12
x | Employees | 137 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.18% |
Latest transcript on Nektar Therapeutics
1 day | +3.68% | ||
1 week | -5.37% | ||
Current month | +50.93% | ||
1 month | +54.35% | ||
3 months | +176.47% | ||
6 months | +194.12% | ||
Current year | +149.56% |
Managers | Title | Age | Since |
---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 71 | 06-12-31 |
Robert Chess
CHM | Chairman | 66 | 91-11-30 |
Sandra Gardiner
DFI | Director of Finance/CFO | 58 | 23-04-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
R. Scott Greer
BRD | Director/Board Member | 65 | 09-12-31 |
Roy A. Whitfield
BRD | Director/Board Member | 70 | 00-07-31 |
Robert Chess
CHM | Chairman | 66 | 91-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.32% | 16 M€ | -6.73% | ||
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 1.405 | -1.06% | 331 982 |
24-04-23 | 1.42 | +4.41% | 1,101,026 |
24-04-22 | 1.36 | +9.68% | 1,970,248 |
24-04-19 | 1.24 | -6.06% | 4,717,823 |
24-04-18 | 1.32 | -2.22% | 3,575,770 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+149.56% | 261M | |
+27.92% | 672B | |
+26.99% | 570B | |
-4.59% | 360B | |
+16.38% | 321B | |
+9.39% | 300B | |
+7.44% | 217B | |
+6.37% | 199B | |
-8.92% | 204B | |
-8.58% | 149B |
- Stock Market
- Equities
- NKTR Stock